Kanti Rai, MD, Oncology, New Hyde Park, NY, Glen Cove Hospital

KantiRaiMD

Oncology New Hyde Park, NY

Hematologic Oncology

Professor of Medicine, Albert Einstein College of Medicine

Dr. Rai is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rai's full profile

Already have an account?

Education & Training

  • North Shore-Long Island Jewish Health System
    North Shore-Long Island Jewish Health SystemRESIDENCY
  • North Shore-Long Island Jewish Health System
    North Shore-Long Island Jewish Health SystemRESIDENCY
  • Lincoln Medical and Mental Health Center
    Lincoln Medical and Mental Health CenterINTERNSHIP
  • Sawai Man Singh Medical College
    Sawai Man Singh Medical CollegeMEDICAL_SCHOOL

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1968 - 2022
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2002-2014
  • Newsday - Top Doctors on Long Island Castle Connolly, 2008, 2010-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?
    Kanti R Rai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia
    Kanti R Rai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By BrutonÍs Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrut...
    Kanti R Rai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • CLL Intraclonal Fractions Defined By Time Since Cell Birth/Division Promote a Leukemia-Supportive, Immune-Tolerant Microenvironment By Distinct Mechanisms 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

Press Mentions

  • Drug Offers Hope Against a Tough-to-Treat Blood Cancer
    Drug Offers Hope Against a Tough-to-Treat Blood Cancer
  • Drug Duo May Be a Weapon Against a Common Leukemia
    Drug Duo May Be a Weapon Against a Common LeukemiaAugust 11, 2019
  • Drug Duo May Be a Weapon Against a Common Leukemia
    Drug Duo May Be a Weapon Against a Common Leukemia
  • Join now to see all

Hospital Affiliations